SOURCE: Leerink Swann & Company

May 03, 2006 13:11 ET

Larry Greenwald Has Joined the Investment Banking Firm of Leerink Swann & Company as Senior Managing Director and Head of Sales Trading

BOSTON, MA -- (MARKET WIRE) -- May 3, 2006 -- Leerink Swann & Company announced today that Larry Greenwald has joined the investment banking firm as Head of Sales Trading. He joins Leerink Swann after seven years at RBC Capital Markets where he was most recently Head of U.S. Sales Trading. Mr. Greenwald has 25 years of experience on Wall Street. He will be responsible for managing the Sales Trading Department and covering select accounts. He will be based in the firm's New York City office and will report directly to the Head of Institutional Equities, Greg Coleman.

"Larry is a terrific addition to our firm," said Jeffrey A. Leerink, CEO and Chairman of Leerink Swann. "He knows the institutional client base in New York. His knowledge and experience will be a great asset to the firm as we continue build out a world class trading capability."

Mr. Greenwald began his professional career at Pfizer as a Product Manager in its antibiotics division. He joined Wall Street in 1981 at Sanford Bernstein, where he became a Partner, working in both sales and trading. He left Bernstein and spent five years building an asset management company and upon returning to the sell-side, he worked briefly at Bear Stearns and Raymond James before joining RBC Capital Markets.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2005 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. Through its internal team of experts and its dedicated external network of academic and community healthcare professionals, MEDACorp assesses the viability of cutting-edge medical technologies, thus giving decision makers the information they need to perform. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    Gregory S. Coleman
    Leerink Swann & Company